Clinical trials: Nervous System Disorders
Neurological Disorders
Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be…
- Trial name
- NCT05212727
- Testing
- Eye-tracking
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Innodem Neurosciences
Myotonic Dystrophy 1
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
- Trial name
- NCT07220603
- Testing
- PGN-EDODM1
- Where
- 3 sites in Canada
- Volunteers
- 48 people
- Sponsor
- PepGen Inc
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Muscular Dystrophy, Duchenne, Muscular Dystrophies
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.
- Conditions
- Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases
- Trial name
- NCT03179631
- Testing
- Ataluren
- Where
- 64 sites in United States, Australia and 16 more
- Volunteers
- 360 people
- Sponsor
- PTC Therapeutics
Alzheimer Disease, Dementia
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
The goal of this Phase 2 Open Label study is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with Alzheimer's Disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05522387
- Testing
- XPro1595
- Where
- 4 sites in Australia
- Volunteers
- 11 people
- Sponsor
- Inmune Bio, Inc.
Sleep Apnea Syndromes
Validation of Withings Sleep for the Detection of Sleep Apnea Syndrome
Sleep Apnea Syndrome (SAS) is a common pathology affecting between 4 and 8% of the general population. It aggravates morbidity and cardio-metabolic mortality and is responsible for accidents related to vigilance disorders.
- Trial name
- VPASS (NCT04234828)
- Where
- 2 sites in Belgium, France
- Volunteers
- 200 people
- Sponsor
- Withings
Myotonic Dystrophy 1
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1).
- Trial name
- FREEDOM-DM1 (NCT06204809)
- Testing
- PGN-EDODM1 for infusion
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 24 people
- Sponsor
- PepGen Inc
Alzheimer's Disease
Open-label Extension Study in Participants With Early Alzheimer's Disease
The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190).
- Trial name
- NCT07105709
- Testing
- GSK4527226
- Where
- 33 sites in United States, Argentina and 9 more
- Volunteers
- 220 people
- Sponsor
- GlaxoSmithKline
Cerebrospinal; Disorder
External Ventricular Drainage Post-Market Clinical Follow-up Registry
This post-market follow-up registry will capture clinical data specific to the safety and performance of the Integra External Ventricular Drainage Systems and Accessories.
- Trial name
- NCT05652296
- Testing
- External Ventricular Drainage (EVD)
- Where
- 4 sites in Belgium, France
- Volunteers
- 120 people
- Sponsor
- Integra LifeSciences Corporation
Stroke, Ischemic Stroke
Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes
Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours…
- Conditions
- Stroke, Ischemic Stroke, Cerebrovascular Disorders, Brain Diseases
- Trial name
- GRASSROOT Reg (NCT07335185)
- Testing
- Supernova revascularization device
- Volunteers
- 3,000 people
- Sponsor
- Gravity Medical Technology, INC
Parkinson Disease
Open-label Trial in Parkinson's Disease (PD)
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
- Trial name
- TEMPO-4 (NCT04760769)
- Testing
- Tavapadon
- Where
- 140 sites in United States, Australia and 12 more
- Volunteers
- 992 people
- Sponsor
- AbbVie
Parkinson Disease
Flexible-Dose Trial in Early Parkinson's Disease (PD)
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
- Trial name
- TEMPO-2 (NCT04223193)
- Testing
- Tavapadon
- Where
- 53 sites in United States, Australia and 11 more
- Volunteers
- 304 people
- Sponsor
- AbbVie
Krabbe Disease
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT
This is a non-blinded, non-randomized dose escalation study of intravenous FBX-101 in which subjects will receive a single infusion of an adeno-associated virus gene therapy product, after more than 21 days of the HSCT (UCBT…
- Trial name
- REKLAIM (NCT05739643)
- Testing
- FBX-101
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Forge Biologics, Inc
AMN, AMN Gene Mutation
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
The course of AMN-related disabilities over time is poorly or incompletely understood due to a limited number of patients and lack of treatments.
- Conditions
- AMN, AMN Gene Mutation, X-ALD
- Trial name
- CYGNET (NCT05008874)
- Testing
- Natural History Observation
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- SwanBio Therapeutics, Inc.
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Central Nervous System Diseases, Pediatric Disorder
Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age
This Phase II open-label, uncontrolled, multicenter trial is designed to investigate the pharmacokinetic (PK) profile of gadopiclenol in plasma, in pediatric patients aged up to 23 months inclusive (term neonates or preterm…
- Conditions
- Central Nervous System Diseases, Pediatric Disorder, Body Indication
- Trial name
- NCT05590884
- Testing
- Gadopiclenol
- Where
- 11 sites in United States, Hungary and 1 more
- Volunteers
- 36 people
- Sponsor
- Guerbet
Neurological Disorder
Safety and Tolerability of Glyceryl Tribenzoate (GTB) Capsules in Healthy Subjects
This study is designed to assess the safety and PK/PD of GTB and Benzoic Acid (Benzoate) using a single ascending dose (SAD) study (under fasting conditions).
- Trial name
- NCT05938452
- Testing
- Glyceryl Tribenzoate
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Forest Hills Lab
Migraine
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101.
- Trial name
- NCT06728553
- Testing
- MTX101
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Manistee Therapeutics
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Brain Metastases, CNS Neoplasm
HyperArc Registry Study
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
- Conditions
- Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial
- Trial name
- NCT05270707
- Testing
- Stereotactic radiosurgery
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 968 people
- Sponsor
- Varian, a Siemens Healthineers Company